Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring

• DOI: 10.1002/ehf2.12850
• Publication Date: 2020-06-27T07:59:21Z
• Authors: Wilfried Mullens; Pieter Martens; Omid Forouzan; Jeroen Dauw; Jan Vercammen; Evert Luwel; Wendy Ceyssens; Veerle Kockaerts; Koen Ameloot; Matthias Dupont
• Keywords: Dapagliflozin

Aims To explore the effects of dapagliflozin on congestion through CardioMEMS (Abbott Inc., Atlanta, USA) and Cordella™ pulmonary artery Sensor (Endotronix Lisle, Il, devices, which are implantable systems that provide real‐time remote monitoring pressure (PAP). Methods results Single‐centre open label observational pilot trial, to investigate short‐term in consecutive heart failure reduced ejection fraction patients with elevated PAP between October December 2019, previously implanted or Sensor. Changes were evaluated an area under curve methodology estimate total sum increase decrease pressures (mmHg/day) for 7 days before after starting relative first day each period. Nine (72 ± 10 years, N‐terminal pro b‐type natriuretic peptide 1027 510 pg/mL, estimated glomerular filtration rate 45 15 mL/kg/m2, left ventricular 35 10%), all optimal guideline‐directed therapy was included. The mean from 42 9.16 38 9.95 mmHg ( P < 0.05). average week leading remained unchanged compared drop observed Interestingly, occurred within 2 stable following start therapy. Conclusions This is study demonstrate a direct effect achieving effective hemodynamic decongestion, providing further mechanistic data regarding potential mechanisms sodium‐glucose co‐transporter‐2 inhibitor benefits failure.